| Terminal complement inhibitor eculizumab in atypical hemolytic–uremic syndrome CM Legendre, C Licht, P Muus, LA Greenbaum, S Babu, C Bedrosian, ... New England Journal of Medicine 368 (23), 2169-2181, 2013 | 1617 | 2013 |
| Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5 FEM Murtagh, JE Marsh, P Donohoe, NJ Ekbal, NS Sheerin, FE Harris Nephrology Dialysis Transplantation 22 (7), 1955-1962, 2007 | 744 | 2007 |
| Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes”(KDIGO) Controversies Conference THJ Goodship, HT Cook, F Fakhouri, FC Fervenza, V Frémeaux-Bacchi, ... Kidney international 91 (3), 539-551, 2017 | 650 | 2017 |
| Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies C Licht, LA Greenbaum, P Muus, S Babu, CL Bedrosian, DJ Cohen, ... Kidney international 87 (5), 1061-1073, 2015 | 448 | 2015 |
| KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation SJ Chadban, C Ahn, DA Axelrod, BJ Foster, BL Kasiske, V Kher, D Kumar, ... Transplantation 104 (4S1), S11-S103, 2020 | 413 | 2020 |
| Urinary tract infections: new insights into a common problem R Kucheria, P Dasgupta, S Sacks, M Khan, N Sheerin Postgraduate medical journal 81 (952), 83, 2005 | 352 | 2005 |
| A genome-wide association study of anorexia nervosa V Boraska, CS Franklin, JAB Floyd, LM Thornton, LM Huckins, L Southam, ... Molecular psychiatry 19 (10), 1085-1094, 2014 | 342 | 2014 |
| Understanding symptoms in patients with advanced chronic kidney disease managed without dialysis: use of a short patient-completed assessment tool EL Murphy, FEM Murtagh, I Carey, NS Sheerin Nephron Clinical Practice 111 (1), c74-c80, 2009 | 231 | 2009 |
| Influence of donor C3 allotype on late renal-transplantation outcome KM Brown, E Kondeatis, RW Vaughan, SP Kon, CKT Farmer, JD Taylor, ... New England Journal of Medicine 354 (19), 2014-2023, 2006 | 203 | 2006 |
| C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy Z Tang, B Lu, E Hatch, SH Sacks, NS Sheerin Journal of the American Society of Nephrology 20 (3), 593-603, 2009 | 177 | 2009 |
| Pivotal role of CD4+ T cells in renal fibrosis following ureteric obstruction TT Tapmeier, A Fearn, K Brown, P Chowdhury, SH Sacks, NS Sheerin, ... Kidney international 78 (4), 351-362, 2010 | 163 | 2010 |
| Trajectories of illness in stage 5 chronic kidney disease: a longitudinal study of patient symptoms and concerns in the last year of life FEM Murtagh, NS Sheerin, J Addington-Hall, IJ Higginson Clinical Journal of the American Society of Nephrology 6 (7), 1580-1590, 2011 | 159 | 2011 |
| Contribution of renal secreted complement C3 to the circulating pool in humans S Tang, W Zhou, NS Sheerin, RW Vaughan, SH Sacks The Journal of Immunology 162 (7), 4336-4341, 1999 | 145 | 1999 |
| Apical proteins stimulate complement synthesis by cultured human proximal tubular epithelial cells S TANG, NS SHEERIN, W ZHOU, Z BROWN, SH SACKS Journal of the American Society of Nephrology 10 (1), 69-76, 1999 | 137 | 1999 |
| Protection against anti-glomerular basement membrane (GBM)-mediated nephritis in C3-and C4-deficient mice NS Sheerin, T Springall, MC Carroll, B Hartley, SH Sacks Clinical & Experimental Immunology 110 (3), 403-409, 1997 | 137 | 1997 |
| Urinary tract infection NS Sheerin Medicine 39 (7), 384-389, 2011 | 134 | 2011 |
| Synthesis of complement protein C3 in the kidney is an important mediator of local tissue injury NS Sheerm, P Risley, K Abe, Z Tang, W Wong, T Lin, SH Sacks The FASEB Journal 22 (4), 1065-1072, 2008 | 116 | 2008 |
| Toll-like receptors TLR2 and TLR4 initiate the innate immune response of the renal tubular epithelium to bacterial products P Chowdhury, SH Sacks, NS Sheerin Clinical & Experimental Immunology 145 (2), 346-356, 2006 | 116 | 2006 |
| Epithelial secretion of C3 promotes colonization of the upper urinary tract by Escherichia coli T Springall, NS Sheerin, K Abe, VM Holers, H Wan, SH Sacks Nature medicine 7 (7), 801-806, 2001 | 111 | 2001 |
| A national specialized service in England for atypical haemolytic uraemic syndrome—the first year’s experience NS Sheerin, D Kavanagh, THJ Goodship, S Johnson QJM: An International Journal of Medicine 109 (1), 27-33, 2016 | 108 | 2016 |
Prof David KavanaghProfessor of Complement Therapeutics, National Renal Complement Therapeutics CentreVerified email at ncl.ac.uk
